Ophthalmologists and researchers have made great strides in the management of glaucoma. From implants and robotics to proper administration of eye drops, glaucoma is treated more effectively than ever. This article highlights some of the latest discoveries in glaucoma, including work by UF startup and Sid Martin Biotech company TearClear.
TearClear has announced the TC-002 phase 3 trial has been successfully initiated. TearClear’s phase 3 trial (CLEAR Study) is a prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TC-002 ophthalmic solution (TearClear Preservative-Free Latanoprost Ophthalmic Solution 0.005%) compared to marketed Latanoprost ophthalmic solution 0.005%.
Glaucoma specialist, Dr. Amy Mehta, discusses new and upcoming developments in glaucoma treatment, including an advance by UF startup and UF Innovate | Accelerate at Sid Martin Biotech company TearClear.
UF startup and UF Innovate | Sid Martin Biotech company TearClear, a late clinical-stage ophthalmic pharmaceutical company, has filed an Investigational New Drug (IND) application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution, 0.005%.
UF startup and UF Innovate | Sid Martin Biotech resident client TearClear has appointed Stuart Raetzman as interim CEO and is preparing for a pivotal study on proprietary latanoprost for glaucoma treatment, according to a press release.
UF startup and UF Innovate | Sid Martin Biotech resident client TearClear, an emerging ophthalmic pharmaceutical company, continues to make progress on the development of its first-in-class platform of preservative-free topical medications.
UF startup and UF Innovate | Sid Martin Biotech resident client TearClear, an emerging ophthalmic pharmaceutical company, announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for the preservative free multi-dose delivery of a proprietary Latanoprost formulation, including the clinical study design for the registration study.